Form 4: Eloxx Pharmaceuticals Director Steven D. Rubin Acquires Shares Through Vesting of Restricted Stock Units

Director Steven D. Rubin acquired 3,750 shares of Eloxx Pharmaceuticals common stock through the vesting of restricted stock units.

Summary

• Steven D. Rubin, a director at Eloxx Pharmaceuticals, acquired 3,750 shares of common stock on January 24, 2025.
• The acquisition was a result of the vesting of restricted stock units (RSUs).
• These RSUs were granted previously and vest over time, with 50% vesting on the first anniversary of January 24, 2024, and the remaining amount in two equal annual installments thereafter.
• Following this transaction, Mr. Rubin directly owns 15,750 shares of Eloxx Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is a positive sign of alignment between management and shareholders, but not a major event.

Positives

• The vesting of restricted stock units aligns the director's interests with the company's long-term performance.
• The increase in direct ownership demonstrates the director's continued commitment to the company.

Industry Context

This is a standard transaction for company directors who are often granted stock options or restricted stock units as part of their compensation package. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• The vesting schedule of the restricted stock units, with 50% vesting on the first anniversary and the remainder over the next two years, is a common practice in the pharmaceutical industry for aligning executive compensation with long-term company performance.
• Many comparable companies, such as BioMarin Pharmaceutical and Vertex Pharmaceuticals, use similar vesting schedules for their executive stock grants.
• The acquisition of shares through vesting is a standard practice and does not indicate any unusual activity compared to industry norms.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it demonstrates the director's continued commitment to the company.

Key Dates

Keywords

Eloxx Pharmaceuticals, Steven D. Rubin, restricted stock units, share acquisition, director, vesting, insider trading